Table 2 Distribution of clinical end-points by quartiles of concentrations of CA 15-3.

From: CA 15-3 prognostic biomarker in SARS-CoV-2 pneumonia

 

Overall

CA15-3

p

[1.95,10.8]

[10.8,17.1]

[17.1,25.3]

[25.3,190]

n

539

129

131

130

130

 

Death

56 (10.4)

4 (3.1)

8 (6.1)

12 (9.2)

31 (23.8)

< 0.001

Intensive care

78 (14.5)

9 (7.0)

14 (10.9)

22 (16.9)

33 (25.4)

< 0.001

WHO maximal

4.09 ± 1.34

3.71 ± 0.89

4.02 ± 1.20

4.10 ± 1.25

4.62 ± 1.74

< 0.001

WHO at discharge

3.14 ± 1.72

2.73 ± 1.11

2.95 ± 1.43

3.06 ± 1.71

3.92 ± 2.26

< 0.001

Length of stay, days

6 [4, 10]

5 [3, 8.75]

8 [5, 11]

6 [4, 9]

7 [4, 11.5]

0.003

O2 at discharge

64 (13.3)

12 (9.6)

15 (12.2)

18 (15.5)

19 (19.2)

0.029

Back to article page